查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年人类类器官市场预测：按产品、可用性、应用、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383372

2030 年人类类器官市场预测：按产品、可用性、应用、最终用户和地区进行的全球分析

Human Organoids Market Forecasts to 2030 - Global Analysis By Product (Kidney, Colorectal, Liver, Pancreas, Heart and Other Products), Usabilty, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球人类类器官市场规模为 23.8 亿美元，预计 2030 年将达到 80.4 亿美元。

人类类器官是人类细胞和组织的簇，其功能类似器官。它是由人体干细胞製成的三维繫统。这使得以惊人的精度再现人体器官的结构和功能成为可能。除了动物模型之外，人类类器官为人类疾病的研究提供了丰富的机会。对遗传异常、癌症、感染疾病等各种疾病的研究已经彻底改变。它也被用于对人类干细胞进行基因工程，并使用来自患者的切片检查样本而不是干细胞来治疗疾病。

根据世界卫生组织（WHO）的数据，截至2018年，北美地区GDP的16.416%用于医疗保健领域。

器官移植的进展

随着人类类器官的引入，器官移植领域也取得了长足的进展。用于移植的器官可以从类器官中获得，无需器官捐赠者。器官移植有助于解决与器官移植相关的道德难题，例如缺乏可用的捐赠者以及器官贩运的道德影响。透过在植入前进行广泛的测试和调整，我们可以降低这些风险并提高手术安全性和成功率。这些因素正在推动市场扩张。

缺乏熟练的专业人员

需要技术人员和研究人员等技术纯熟劳工来推出、进行、记录结果、收集资料和评估类器官研究。对基本科学概念理解不够、选择合适的方法不仅增加了研究人员和服务提供者的工作量和时间限制，而且还会产生各种直接和间接成本。因此，需要高素质的人员来进行解释、方法开发、检验、操作和故障排除。这是市场拓展的障碍。

越来越重视替代方法的开发

医学研究经常使用动物模型来研究人类特有的疾病。然而，有一些例子，例如药物毒性研究，显示动物模型不一定是人类药物反应的可靠预测因子。这是因为人类的药物代谢和毒物代谢与动物显着不同，利用实验小鼠等模型研究药物代谢极为困难。儘管目前的重点是减少研究中动物的使用，但类器官有望推动市场成长，因为它们可以作为动物模型的可行替代品。

3D 细胞培养基础设施不足

拥有采用尖端方法所需的工具是进行基于 3D 细胞培养的研究的要求之一。将类器官纳入目前的研究方法存在许多技术障碍，因为类器官的生产既耗时又耗资。此外，建立 3D 单元製造的基础设施和设备需要大量成本和时间。这是阻碍市场拓展的因素。

COVID-19 的影响：

人类类器官市场受到 COVID-19 爆发的严重影响。在大流行期间，随着疫苗上市的研发工作迅速增加，类器官的使用增加。类器官在大流行期间被广泛用于药物研究的主要原因包括它们与真实器官的相似性、细胞向性、细胞活力和其他考虑因素。

在预测期内，发育生物学领域预计将是最大的。

在预测期内，发育生物学领域预计将是最大的。配子发生、受精、胚胎发育、成体发育和老化的过程都包含在发育生物学中。从培养的干细胞和组织中创造类器官、架构是可能的。人类类器官培养提供了一个机会来研究人类发育并在使用非人类模型物种的研究中经常看到的详细程度模拟疾病过程。

预计生技公司在预测期内的复合年增长率最高。

生技公司领域预计在预测期内复合年增长率最高。在药物开发过程和随后的监管备案过程中，这些公司需要提供与药物开发相关的某些资料。遵守监管标准需要在早期开发和阶段提供广泛的服务。由于创造新的治疗化合物相关的技术和监管障碍，製药和生物技术公司面临时间和成本的复杂问题。

比最大的地区

由于有多家使用类器官 3D 培养技术的製药和生物技术公司，与研究机构和临床实验室合作进行再生医学和药物研发发现开发，预计北美将在预测期内占据最大的市场占有率。每年较高的人均政府医疗支出、有利的政府政策、易于获得的先进技术以及较高的采用率正在推动该地区人类类器官产业的扩张。

复合年增长率最高的地区：

由于经济发展和较低的营运成本，预计亚太地区在预测期内将保持最高的复合年增长率。对生物製药研究和开发的日益重视、药品生产量的增加以及癌症发病率的上升正在推动该地区的市场扩张。此外，政府现代化法律和现行法规限制在药物临床试验中使用动物试验。因此，在整个临床试验和其他药物开发过程中，正在采取不同的方法进行药物测试。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球人类类器官市场：副产品

  • 介绍
  • 肾
  • 大肠直肠
  • 肝
  • 胰臟
  • 心
  • 其他产品

第6章全球人类类器官市场：依可用性分类

  • 介绍
  • 可客製化产品
  • 即用型产品

第7章全球人体器官市场：依应用分类

  • 介绍
  • 病理
  • 个人化医疗
  • 干细胞研究
  • 再生医学
  • 发育生物学

第8章全球人类类器官市场：依最终使用者分类

  • 介绍
  • 学术研究所
  • 药品
  • 生技公司
  • 医院
  • 诊断中心
  • 其他最终用户

第9章全球人类类器官市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Hurel Corporation
  • BioIVT
  • Organovo
  • Kaly-Cell
  • HUB Organoids
  • Thermo Fisher Scientific
  • Kirkstall
  • InSphero
  • Corning Incorporated
  • Kerafast
  • ZenBio
  • CN Bio Innovations
  • Stemcell Technologies
  • Promethera Biosciences
  • Biopredic International
  • Cyfuse Biomedical
  • System1 Biosciences, Inc.
  • Mimetas
Product Code: SMRC24222

According to Stratistics MRC, the Global Human Organoids Market is accounted for $2.38 billion in 2023 and is expected to reach $8.04 billion by 2030 growing at a CAGR of 19% during the forecast period. Human organoids are developed masses of human cells or tissue that have an organ-like function. It's a three-dimensional system made of human stem cells. This has allowed for the remarkably accurate replication of the structure and functionality of human organs. Human organoids provide a wealth of opportunities for the study of human illness in addition to animal models. The study of different diseases, such as genetic abnormalities, cancer, and infectious diseases, has revolutionized. They are employed in the genetic engineering of human stem cells and, in lieu of stem cells, in the treatment of disease using biopsy samples from patients.

According to the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America.

Market Dynamics:

Driver:

Higher procedure of organ transplantation

The field of organ transplantation has advanced significantly with the introduction of human organoids, which may lead to improved protocols and results. Organs for transplantation can be obtained from organoids without the need for organ donors. They assist in resolving moral conundrums related to organ transplantation, such as the scarcity of available donors and the moral implications of organ trafficking. By enabling extensive testing and tuning before to transplantation, they reduce these hazards and enhance operation safety and success rates. These elements are enhancing the market's expansion.

Restraint:

Dearth of skilled professionals

It takes skilled workers, such technicians and researchers, to set up and conduct organoid studies, as well as to record findings, collect data, and evaluate it. Inadequate understanding of the fundamental scientific concepts and appropriate technique selection can lead to various direct and indirect costs, as well as increased workload and time constraints for researchers and service providers. Therefore, highly qualified workers are required for tasks like interpretation, method creation, validation, operation, and troubleshooting. This is the obstacle preventing the market from expanding.

Opportunity:

Growing focus on developing alternatives

In biomedical research, animal models are frequently utilized to study illnesses unique to humans. But there are several instances that show that, like with drug toxicity research, animal models are not necessarily reliable predictors of human drug response. This is due to the fact that human metabolism of medications and poisons differs greatly from that of animals, making it extremely difficult to investigate drug metabolism using experimental models such lab mouse species. The present focus on decreasing animal use in research is projected to assist the market's growth, since organoids can act as viable substitutes for animal models.

Threat:

Inadequate infrastructure for 3D cell culture

Having the tools needed to employ cutting-edge methods is one requirement for carrying out 3D cell culture-based research. The incorporation of organoids into current research processes presents a number of technical hurdles due to the capital- and time-intensive nature of organoid manufacture. Furthermore, it takes a significant amount of money and time to set up the infrastructure and equipment for 3D cell production. This is the element impeding the market's expansion.

COVID-19 Impact:

The human organoids market was impacted significantly by the COVID-19 epidemic. The increased use of organoids during the pandemic was caused by the rapid increase in research and development efforts for the vaccine's release. Some of the main reasons why organoids were widely used in medication research during the pandemic were their similarity to real organs, cell tropism, cell survival, and other considerations.

The developmental biology segment is expected to be the largest during the forecast period

The developmental biology segment is expected to be the largest during the forecast period. The processes of gamete formation, fertilization, embryonic development, adult organism emergence, and senescence are all included in developmental biology. It is possible to create organoids-structures that mimic the in vivo architecture and function of whole organs-from stem cells or tissues grown in culture. Human organoid cultures offer the opportunity to investigate human development and simulate illness processes at the same level of detail that is often associated with studies with nonhuman model species.

The biotechnology companies segment is expected to have the highest CAGR during the forecast period

The biotechnology companies segment is expected to have the highest CAGR during the forecast period. During the medication development process and the subsequent filing of applications to regulatory authorities, these businesses are required to provide particular data relating to drug development. In order to comply with regulatory standards, a broad range of services are required during the early development and clinical phases. Pharmaceutical and biotechnology businesses face time and expense complications as a result of the technical and regulatory obstacles associated with the creation of novel therapeutic compounds.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of several pharmaceutical and biotechnology companies that use organoid 3D culture technology in collaboration with research institutes and clinical laboratories for developing regenerative medicines and drug discovery & development. The governments' large yearly per capita healthcare expenditures, together with favorable government policies and easy access to and high adoption of sophisticated technology, are propelling the expansion of the human organoids industry in this region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to economic development and low operating costs. The increasing emphasis on biopharmaceutical R&D, massive medication manufacturing, and rise in cancer prevalence fuel the market's expansion in this area. Furthermore, the government's modernization act and current rules restrict the use of animal experimentation in medication clinical trials. As a result, throughout clinical trials and other drug development processes, a different approach to drug testing is adopted.

Key players in the market

Some of the key players in Human Organoids market include: Hurel Corporation, BioIVT, Organovo, Kaly-Cell, HUB Organoids , Thermo Fisher Scientific, Kirkstall, InSphero, Corning Incorporated, Kerafast , ZenBio , CN Bio Innovations, Stemcell Technologies, Promethera Biosciences, Biopredic International, Cyfuse Biomedical, System1 Biosciences, Inc. and Mimetas.

Key Developments:

In April 2023, InSphero AG announced that the company is making their patented Akura 96 and 384 Spheroid Microplates available to researchers in the Indian market by signing a distribution agreement with Bionova Supplies in biotechnology and scientific instruments.

In March 2023, Molecular Devices, LLC and HUB Organoids (HUB) announced a strategic collaboration enabling continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition.

In February 2023, Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers.

Products Covered:

  • Kidney
  • Colorectal
  • Liver
  • Pancreas
  • Heart
  • Other Products

Usabilty Covered:

  • Customizable Products
  • Ready to Use Products

Applications Covered:

  • Disease Pathology
  • Personalized Medicine
  • Stem Cell Research
  • Regenerative Medicine
  • Developmental Biology
  • Disease Biomarker Discovery:
  • Drug Toxicity & Efficacy Testing
  • Organ Transplantation
  • Cancer Research
  • Neurological Studies
  • Other Applications

End Users Covered:

  • Academic & Research Institutes
  • Pharmaceutical
  • Biotechnology Companies
  • Hospitals
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Organoids Market, By Product

  • 5.1 Introduction
  • 5.2 Kidney
  • 5.3 Colorectal
  • 5.4 Liver
  • 5.5 Pancreas
  • 5.6 Heart
  • 5.7 Other Products

6 Global Human Organoids Market, By Usabilty

  • 6.1 Introduction
  • 6.2 Customizable Products
  • 6.3 Ready to Use Products

7 Global Human Organoids Market, By Application

  • 7.1 Introduction
  • 7.2 Disease Pathology
  • 7.3 Personalized Medicine
  • 7.4 Stem Cell Research
  • 7.5 Regenerative Medicine
  • 7.6 Developmental Biology

7.7 Disease Biomarker Discovery:

  • 7.8 Drug Toxicity & Efficacy Testing
  • 7.9 Organ Transplantation
  • 7.10 Cancer Research
  • 7.11 Neurological Studies
  • 7.12 Other Applications

8 Global Human Organoids Market, By End User

  • 8.1 Introduction
  • 8.2 Academic & Research Institutes
  • 8.3 Pharmaceutical
  • 8.4 Biotechnology Companies
  • 8.5 Hospitals
  • 8.6 Diagnostic Centers
  • 8.7 Other End Users

9 Global Human Organoids Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Hurel Corporation
  • 11.2 BioIVT
  • 11.3 Organovo
  • 11.4 Kaly-Cell
  • 11.5 HUB Organoids
  • 11.6 Thermo Fisher Scientific
  • 11.7 Kirkstall
  • 11.8 InSphero
  • 11.9 Corning Incorporated
  • 11.10 Kerafast
  • 11.11 ZenBio
  • 11.12 CN Bio Innovations
  • 11.13 Stemcell Technologies
  • 11.14 Promethera Biosciences
  • 11.15 Biopredic International
  • 11.16 Cyfuse Biomedical
  • 11.17 System1 Biosciences, Inc.
  • 11.18 Mimetas

List of Tables

  • Table 1 Global Human Organoids Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Organoids Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Human Organoids Market Outlook, By Kidney (2021-2030) ($MN)
  • Table 4 Global Human Organoids Market Outlook, By Colorectal (2021-2030) ($MN)
  • Table 5 Global Human Organoids Market Outlook, By Liver (2021-2030) ($MN)
  • Table 6 Global Human Organoids Market Outlook, By Pancreas (2021-2030) ($MN)
  • Table 7 Global Human Organoids Market Outlook, By Heart (2021-2030) ($MN)
  • Table 8 Global Human Organoids Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 9 Global Human Organoids Market Outlook, By Usabilty (2021-2030) ($MN)
  • Table 10 Global Human Organoids Market Outlook, By Customizable Products (2021-2030) ($MN)
  • Table 11 Global Human Organoids Market Outlook, By Ready to Use Products (2021-2030) ($MN)
  • Table 12 Global Human Organoids Market Outlook, By Application (2021-2030) ($MN)
  • Table 13 Global Human Organoids Market Outlook, By Disease Pathology (2021-2030) ($MN)
  • Table 14 Global Human Organoids Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 15 Global Human Organoids Market Outlook, By Stem Cell Research (2021-2030) ($MN)
  • Table 16 Global Human Organoids Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 17 Global Human Organoids Market Outlook, By Developmental Biology (2021-2030) ($MN)
  • Table 18 Global Human Organoids Market Outlook, By Disease Biomarker Discovery: (2021-2030) ($MN)
  • Table 19 Global Human Organoids Market Outlook, By Drug Toxicity & Efficacy Testing (2021-2030) ($MN)
  • Table 20 Global Human Organoids Market Outlook, By Organ Transplantation (2021-2030) ($MN)
  • Table 21 Global Human Organoids Market Outlook, By Cancer Research (2021-2030) ($MN)
  • Table 22 Global Human Organoids Market Outlook, By Neurological Studies (2021-2030) ($MN)
  • Table 23 Global Human Organoids Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 Global Human Organoids Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Human Organoids Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)
  • Table 26 Global Human Organoids Market Outlook, By Pharmaceutical (2021-2030) ($MN)
  • Table 27 Global Human Organoids Market Outlook, By Biotechnology Companies (2021-2030) ($MN)
  • Table 28 Global Human Organoids Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Human Organoids Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 30 Global Human Organoids Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.